Medication Response™

About MyOme

MyOme operates at the intersection of genetics, bioinformatics, and clinical care, offering a comprehensive whole-genome-based testing platform. Its core innovation is the integrated Polygenic Risk Score (iPRS™), which combines monogenic and polygenic risk data validated across diverse ancestries. The company targets multiple customer segments, including providers, patients, employers, and healthcare systems, with a focus on making precision medicine actionable in primary care settings. MyOme is a private, commercial-stage company with key partnerships, such as with Illumina and Broad Clinical Labs, enhancing its technological and distribution capabilities.

Therapeutic Areas

Other Pharmacogenomics Drugs